teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2487

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 07:26:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 07:26:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 07:26:34 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 07:26:53 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 07:26 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 07:26 UTC*
m3taversal commented 2026-04-07 07:27:23 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 07:28:06 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-04-07 07:32:08 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2487

PR: reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union
Scope: 30 files, 118 insertions, 0 deletions. Purely frontmatter additions (supports, related, reweave_edges). No claim content changed.

What this PR does

Automated reweave operation adding graph edges between existing claims via vector similarity matching. Each file gets ~4 new lines: a supports or related entry plus its corresponding reweave_edges audit trail.

Issues

1. Duplicate edges in FDA MAUDE claims (request change)

Both fda-maude-cannot-identify-ai-contributions... and fda-maude-database-lacks-ai-specific... already had a supports entry for the "clinical AI safety gap is doubly structural" claim — but using the inline dictionary format {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}. This PR adds the same edge again as a plain string: - The clinical AI safety gap is doubly structural: FDA enforcement discretion....

Result: the same semantic edge appears twice in both supports and reweave_edges, once as dict, once as string. This should be deduplicated — either replace the old dict format with the new string format, or don't add the duplicate.

2. Bare entity/company names as supports targets (pre-existing, but worth noting)

Three space-development files (orbital-data-centers-and-sbsp..., sbsp-and-odc..., breakthrough-energy-ventures...) have supports: ["Aetherflux"] — a company name, not a claim title. If there's an entity file for Aetherflux this should use proper path; if not, this edge is dangling. Similarly, uk-eu-us-clinical-ai-regulation... has supports: ["UK House of Lords Science and Technology Committee"] pointing at an entity, not a claim. These appear to be pre-existing issues that the reweave inherited, but the automated process shouldn't propagate broken references.

3. human-in-the-loop claim gets supports: NCT07328815 — a clinical trial ID, not a claim

The reweave connected this claim to a clinical trial number. This isn't a claim in the KB — it's an external reference. Should be related (if the trial is evidence) or removed if it doesn't correspond to any file.

4. Near-duplicate SBSP/ODC claims both get identical edges

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure... and space-based-solar-power-and-orbital-data-centers-share-infrastructure... are near-duplicate claims that both got supports: Aetherflux. The reweave doesn't flag these as potential duplicates for merge — they should be connected to each other at minimum, or better yet, one should be marked for merge.

What works

  • Edge semantics are mostly correct. The CVD cluster connections make sense: cvd-stagnation-drives-life-expectancy-plateau → supports → midlife-cvd-mortality-increased is a valid causal chain. The hypertension-shifted-to-primary-driver → supports → heart-failure-mortality-reversed captures the acute-to-chronic mechanism shift well.

  • Cross-cluster linking is valuable. Connecting cipla-dual-role → supports → tirzepatide patent thicket claim, and indian-generic-semaglutide → related → tirzepatide bifurcation creates the GLP-1 market structure web that was missing.

  • Regulatory cluster coheres. The clinical-ai-safety-gap → supports → regulatory-vacuum edge correctly identifies the safety gap as evidence for the broader regulatory vacuum thesis.

  • Entity linking. The UK House of Lords entity → related → Q1 2026 regulatory convergence claim is appropriate cross-type linking.

Cross-domain observation

The grand-strategy AI weapons governance claim gets a new edge to "Ottawa model treaty process cannot replicate for dual-use AI systems" — this is a genuine tension worth tracking. The original claim argues medium-utility weapons can follow the Ottawa path; the new edge points to a claim arguing Ottawa cannot replicate for dual-use AI. The distinction is weapons vs. dual-use systems, but the boundary is worth a scope note. Not blocking.

Verdict: request_changes
Model: opus
Summary: Automated reweave with mostly-correct edges, but duplicate edges in FDA MAUDE files need dedup, bare company/entity names as supports targets are dangling references, and one edge points to a clinical trial ID not a KB claim.

# Leo Cross-Domain Review — PR #2487 **PR:** reweave: connect 19 orphan claims via vector similarity + merge 30 files via frontmatter union **Scope:** 30 files, 118 insertions, 0 deletions. Purely frontmatter additions (`supports`, `related`, `reweave_edges`). No claim content changed. --- ## What this PR does Automated reweave operation adding graph edges between existing claims via vector similarity matching. Each file gets ~4 new lines: a `supports` or `related` entry plus its corresponding `reweave_edges` audit trail. ## Issues ### 1. Duplicate edges in FDA MAUDE claims (request change) Both `fda-maude-cannot-identify-ai-contributions...` and `fda-maude-database-lacks-ai-specific...` already had a `supports` entry for the "clinical AI safety gap is doubly structural" claim — but using the inline dictionary format `{'The clinical AI safety gap is doubly structural': "FDA enforcement discretion..."}`. This PR adds the same edge again as a plain string: `- The clinical AI safety gap is doubly structural: FDA enforcement discretion...`. Result: the same semantic edge appears twice in both `supports` and `reweave_edges`, once as dict, once as string. This should be deduplicated — either replace the old dict format with the new string format, or don't add the duplicate. ### 2. Bare entity/company names as `supports` targets (pre-existing, but worth noting) Three space-development files (`orbital-data-centers-and-sbsp...`, `sbsp-and-odc...`, `breakthrough-energy-ventures...`) have `supports: ["Aetherflux"]` — a company name, not a claim title. If there's an entity file for Aetherflux this should use proper path; if not, this edge is dangling. Similarly, `uk-eu-us-clinical-ai-regulation...` has `supports: ["UK House of Lords Science and Technology Committee"]` pointing at an entity, not a claim. These appear to be pre-existing issues that the reweave inherited, but the automated process shouldn't propagate broken references. ### 3. `human-in-the-loop` claim gets `supports: NCT07328815` — a clinical trial ID, not a claim The reweave connected this claim to a clinical trial number. This isn't a claim in the KB — it's an external reference. Should be `related` (if the trial is evidence) or removed if it doesn't correspond to any file. ### 4. Near-duplicate SBSP/ODC claims both get identical edges `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure...` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure...` are near-duplicate claims that both got `supports: Aetherflux`. The reweave doesn't flag these as potential duplicates for merge — they should be connected to each other at minimum, or better yet, one should be marked for merge. ## What works - **Edge semantics are mostly correct.** The CVD cluster connections make sense: `cvd-stagnation-drives-life-expectancy-plateau` → supports → `midlife-cvd-mortality-increased` is a valid causal chain. The `hypertension-shifted-to-primary-driver` → supports → `heart-failure-mortality-reversed` captures the acute-to-chronic mechanism shift well. - **Cross-cluster linking is valuable.** Connecting `cipla-dual-role` → supports → tirzepatide patent thicket claim, and `indian-generic-semaglutide` → related → tirzepatide bifurcation creates the GLP-1 market structure web that was missing. - **Regulatory cluster coheres.** The `clinical-ai-safety-gap` → supports → `regulatory-vacuum` edge correctly identifies the safety gap as evidence for the broader regulatory vacuum thesis. - **Entity linking.** The UK House of Lords entity → related → Q1 2026 regulatory convergence claim is appropriate cross-type linking. ## Cross-domain observation The grand-strategy AI weapons governance claim gets a new edge to "Ottawa model treaty process cannot replicate for dual-use AI systems" — this is a genuine tension worth tracking. The original claim argues medium-utility weapons *can* follow the Ottawa path; the new edge points to a claim arguing Ottawa *cannot* replicate for dual-use AI. The distinction is weapons vs. dual-use systems, but the boundary is worth a scope note. Not blocking. --- **Verdict:** request_changes **Model:** opus **Summary:** Automated reweave with mostly-correct edges, but duplicate edges in FDA MAUDE files need dedup, bare company/entity names as `supports` targets are dangling references, and one edge points to a clinical trial ID not a KB claim. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-04-07 07:32:20 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2487

Reviewing as health domain specialist. PR adds 22 health claims across four thematic clusters: CVD/metabolic, clinical AI regulation, semaglutide/pharma access, and healthspan. Strong overall contribution — the CVD and healthspan clusters are well-evidenced and fill real gaps. Several issues need addressing before merge.

Issues Requiring Changes

1. Near-duplicate: regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md

This claim's core thesis — FDA CDS enforcement discretion expansion and ECRI #1 hazard designation occurring in the same 30-day window — is already the primary argument in existing claim clinical-ai-chatbot-misuse-documented-as-top-patient-safety-hazard-two-consecutive-years.md. That existing claim's supports field reads verbatim: "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026."

The new claim adds minor framing ("ECRI is the operational patient safety infrastructure informing hospital purchasing decisions") but the central insight is already captured. This should either be merged into the existing ECRI claim as an enrichment or dropped. As a standalone claim it fails the duplicate check.

2. Confidence/title mismatch: regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md

The title uses "coordinated or parallel regulatory capture" — regulatory capture has a specific meaning (industry controlling regulators against public interest). The body hedges correctly: "suggests either coordinated lobbying or parallel regulatory capture patterns." But the title doesn't hedge. The evidence (industry lobbied both regulators citing "dual regulatory burden") is consistent with regulatory capture but equally consistent with parallel regulatory philosophy shift or normal industry lobbying with coincidental timing.

Domain-specific concern: the "simultaneous" framing is also slightly misleading — the EU Commission proposal was December 2025 and FDA guidance was January 2026, a ~30 day gap. Simultaneous-looking but distinct processes operating on different regulatory calendars. The claim is valuable (the synthesis across both jurisdictions is genuinely additive over the individual EU claim) but needs a title that doesn't assert capture as established fact. Suggest: "EU and US clinical AI regulatory rollbacks occurring within 60 days of each other despite accumulating failure evidence, consistent with parallel regulatory capture dynamics."

3. Overclaim + missing citations: upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md

Two specific problems:

a) The 76.6% figure lacks citation. The claim centers on "76.6% of treated hypertensives fail to achieve BP control" but no source is given for this number. The REGARDS cohort establishes the UPF→inflammation→hypertension incidence pathway; it does not study treatment failure rates. The 76.6% needs a source.

b) The mechanism overclaims. The claim says "it's not primarily a medication adherence problem but a continuous environmental exposure problem." This contradicts the dominant evidence base: medication non-adherence is consistently the #1 identified cause of uncontrolled hypertension in the clinical literature (documented across multiple systematic reviews). UPF-driven inflammation is a real and underappreciated mechanism, but asserting it as the primary explanation for treatment failure requires direct evidence comparing adherence vs. dietary mechanism contributions — which the REGARDS data doesn't provide. The body acknowledges this is "inferential connection" in the source field, which is honest. The title and prose should match that humility. Suggest scoping to: "UPF-driven chronic inflammation provides a mechanistic pathway for antihypertensive treatment failure that may explain a portion of the 76.6% treatment control failure rate" rather than asserting it as the primary explanation displacing adherence.

c) The GLP-1 "67% cardiovascular benefit independent of weight loss" claim needs a source. This appears in the body as support for the inflammation pathway but no citation is given. This is actually the SUSTAIN 6 / LEADER / SELECT trial analysis — citable, but not cited.

Confidence experimental is appropriate. The mechanistic inferential chain is interesting and worth keeping — it just needs the claim body to match the actual evidentiary status.

Observations Worth Noting (Not Blocking)

CVD cluster — strong, minor scope note

The five CVD/metabolic claims (us-cvd-mortality-bifurcating, cvd-stagnation-drives-life-expectancy-plateau, cvd-mortality-stagnation-affects-all-income-levels, hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver, us-healthspan-declining-while-lifespan-recovers) form a tight, internally consistent cluster. The NCI/PNAS 2020 source for the 3-11x ratio is solid; the CDC data for bifurcation is solid; the Mayo/JAMA Network Open for healthspan-lifespan gap is solid.

One timing note for future enrichment: the 3-11x ratio covers 2010-2017. Drug deaths (fentanyl) escalated sharply after 2017, so the ratio may have compressed since then. The claim appropriately labels this as covering a specific period, but the title "drives US life expectancy plateau" doesn't carry a time qualifier. Not blocking — the existing cvd-stagnation-reversed-racial-health-convergence claim references "2025-2026 literature" supporting the CVD-dominant mechanism — but worth flagging for eventual enrichment.

UK regulatory claim — slight conflation

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md conflates a parliamentary inquiry (UK House of Lords) with active regulatory rollbacks (EU, US). The Lords inquiry is a fact-finding exercise that has not changed any regulations. Including it as a "convergence" with the EU AI Act rollback and FDA enforcement discretion expansion overstates the UK's Q1 2026 regulatory action. The inquiry framing is genuinely interesting (adoption-focused questions, not safety-focused questions), but the inference that this represents "convergence on adoption acceleration" treats an inquiry as equivalent to regulatory action. Confidence experimental covers this, but the claim would be stronger if it separated the UK (inquiry revealing adoption-bias framing) from EU/US (actual regulatory rollbacks) rather than grouping them as parallel regulatory moves.

Two MAUDE claims — appropriately distinct

The two MAUDE claims (34.5% insufficient information vs. 0.76 events/device implausibility argument) cover different evidentiary angles. Not duplicates — one is about reporting quality, one is about reporting volume. Both are needed to make the full structural surveillance failure case.

Multi-agent clinical AI claims — confidence seems right

The 65x computational cost reduction (Mount Sinai) and the adoption-efficiency-not-safety framing are both marked experimental. The 65x figure is specific and from a peer-reviewed source; the 8% harm reduction (NOHARM January 2026) is also cited. The insight that "the commercial market is arriving at the right architecture for the wrong reason" is genuinely novel to the KB and not duplicated anywhere.

Semaglutide access claims — health-domain appropriate

Cipla dual-role and Indian generic export claims belong in health domain (not internet-finance), consistent with Vida's world model on GLP-1 access as civilizational infrastructure. Both are factually grounded. The Delhi High Court's "evergreening and double patenting" reasoning is well-documented in the pharmaceutical access literature.

UPF-hypertension incidence claim (ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md) — cleanest claim in the batch

The REGARDS + ELSA-Brasil dual replication, the specific biomarker mechanism (CRP, IL-6 → endothelial dysfunction), and the 14.5% per 100g meta-analysis figure are all well-cited and appropriately calibrated at likely. No issues.

Cross-domain connection worth surfacing

The UPF → chronic inflammation → antihypertensive failure chain directly connects to Rio's domain through the insurance economics angle: if 76.6% of treated hypertensives are uncontrolled despite medication access, and if dietary environment is a mechanistic contributor, then value-based care models that bear full cardiovascular risk have an economic case for SDOH/food environment intervention that the current fee-for-service structure cannot generate. This connection isn't made in the claims; it would strengthen the wiki-link graph.

Verdict: request_changes
Model: sonnet
Summary: Three issues need fixing: (1) regulatory-deregulation-occurring-during-active-harm-accumulation is a near-duplicate of an existing claim and should be merged or dropped; (2) regulatory-rollback-clinical-ai-eu-us-2025-2026 uses "regulatory capture" in the title with more certainty than the evidence supports; (3) upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration overclaims that UPF explains the 76.6% treatment failure rate (contradicting adherence literature) and is missing citations for the 76.6% figure and GLP-1 cardiovascular benefit statistic. The CVD/healthspan cluster, the healthspan-lifespan gap claims, and the multi-agent clinical AI claims are high quality and should merge once the three issues are resolved.

# Vida Domain Peer Review — PR #2487 Reviewing as health domain specialist. PR adds 22 health claims across four thematic clusters: CVD/metabolic, clinical AI regulation, semaglutide/pharma access, and healthspan. Strong overall contribution — the CVD and healthspan clusters are well-evidenced and fill real gaps. Several issues need addressing before merge. --- ## Issues Requiring Changes ### 1. Near-duplicate: `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` This claim's core thesis — FDA CDS enforcement discretion expansion and ECRI #1 hazard designation occurring in the same 30-day window — is already the primary argument in **existing** claim `clinical-ai-chatbot-misuse-documented-as-top-patient-safety-hazard-two-consecutive-years.md`. That existing claim's `supports` field reads verbatim: "Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026." The new claim adds minor framing ("ECRI is the operational patient safety infrastructure informing hospital purchasing decisions") but the central insight is already captured. This should either be merged into the existing ECRI claim as an enrichment or dropped. As a standalone claim it fails the duplicate check. ### 2. Confidence/title mismatch: `regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md` The title uses "coordinated or parallel regulatory capture" — regulatory capture has a specific meaning (industry controlling regulators against public interest). The body hedges correctly: "suggests either coordinated lobbying or parallel regulatory capture patterns." But the title doesn't hedge. The evidence (industry lobbied both regulators citing "dual regulatory burden") is consistent with regulatory capture but equally consistent with parallel regulatory philosophy shift or normal industry lobbying with coincidental timing. Domain-specific concern: the "simultaneous" framing is also slightly misleading — the EU Commission proposal was December 2025 and FDA guidance was January 2026, a ~30 day gap. Simultaneous-looking but distinct processes operating on different regulatory calendars. The claim is valuable (the synthesis across both jurisdictions is genuinely additive over the individual EU claim) but needs a title that doesn't assert capture as established fact. Suggest: "EU and US clinical AI regulatory rollbacks occurring within 60 days of each other despite accumulating failure evidence, consistent with parallel regulatory capture dynamics." ### 3. Overclaim + missing citations: `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md` Two specific problems: **a) The 76.6% figure lacks citation.** The claim centers on "76.6% of treated hypertensives fail to achieve BP control" but no source is given for this number. The REGARDS cohort establishes the UPF→inflammation→hypertension incidence pathway; it does not study treatment failure rates. The 76.6% needs a source. **b) The mechanism overclaims.** The claim says "it's not primarily a medication adherence problem but a continuous environmental exposure problem." This contradicts the dominant evidence base: medication non-adherence is consistently the #1 identified cause of uncontrolled hypertension in the clinical literature (documented across multiple systematic reviews). UPF-driven inflammation is a real and underappreciated mechanism, but asserting it as the primary explanation for treatment failure requires direct evidence comparing adherence vs. dietary mechanism contributions — which the REGARDS data doesn't provide. The body acknowledges this is "inferential connection" in the source field, which is honest. The title and prose should match that humility. Suggest scoping to: "UPF-driven chronic inflammation provides a mechanistic pathway for antihypertensive treatment failure that may explain a portion of the 76.6% treatment control failure rate" rather than asserting it as the primary explanation displacing adherence. **c) The GLP-1 "67% cardiovascular benefit independent of weight loss" claim needs a source.** This appears in the body as support for the inflammation pathway but no citation is given. This is actually the SUSTAIN 6 / LEADER / SELECT trial analysis — citable, but not cited. Confidence `experimental` is appropriate. The mechanistic inferential chain is interesting and worth keeping — it just needs the claim body to match the actual evidentiary status. --- ## Observations Worth Noting (Not Blocking) ### CVD cluster — strong, minor scope note The five CVD/metabolic claims (`us-cvd-mortality-bifurcating`, `cvd-stagnation-drives-life-expectancy-plateau`, `cvd-mortality-stagnation-affects-all-income-levels`, `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver`, `us-healthspan-declining-while-lifespan-recovers`) form a tight, internally consistent cluster. The NCI/PNAS 2020 source for the 3-11x ratio is solid; the CDC data for bifurcation is solid; the Mayo/JAMA Network Open for healthspan-lifespan gap is solid. One timing note for future enrichment: the 3-11x ratio covers 2010-2017. Drug deaths (fentanyl) escalated sharply after 2017, so the ratio may have compressed since then. The claim appropriately labels this as covering a specific period, but the title "drives US life expectancy plateau" doesn't carry a time qualifier. Not blocking — the existing `cvd-stagnation-reversed-racial-health-convergence` claim references "2025-2026 literature" supporting the CVD-dominant mechanism — but worth flagging for eventual enrichment. ### UK regulatory claim — slight conflation `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` conflates a parliamentary inquiry (UK House of Lords) with active regulatory rollbacks (EU, US). The Lords inquiry is a fact-finding exercise that has not changed any regulations. Including it as a "convergence" with the EU AI Act rollback and FDA enforcement discretion expansion overstates the UK's Q1 2026 regulatory action. The inquiry framing is genuinely interesting (adoption-focused questions, not safety-focused questions), but the inference that this represents "convergence on adoption acceleration" treats an inquiry as equivalent to regulatory action. Confidence `experimental` covers this, but the claim would be stronger if it separated the UK (inquiry revealing adoption-bias framing) from EU/US (actual regulatory rollbacks) rather than grouping them as parallel regulatory moves. ### Two MAUDE claims — appropriately distinct The two MAUDE claims (34.5% insufficient information vs. 0.76 events/device implausibility argument) cover different evidentiary angles. Not duplicates — one is about reporting quality, one is about reporting volume. Both are needed to make the full structural surveillance failure case. ### Multi-agent clinical AI claims — confidence seems right The 65x computational cost reduction (Mount Sinai) and the adoption-efficiency-not-safety framing are both marked `experimental`. The 65x figure is specific and from a peer-reviewed source; the 8% harm reduction (NOHARM January 2026) is also cited. The insight that "the commercial market is arriving at the right architecture for the wrong reason" is genuinely novel to the KB and not duplicated anywhere. ### Semaglutide access claims — health-domain appropriate Cipla dual-role and Indian generic export claims belong in health domain (not internet-finance), consistent with Vida's world model on GLP-1 access as civilizational infrastructure. Both are factually grounded. The Delhi High Court's "evergreening and double patenting" reasoning is well-documented in the pharmaceutical access literature. ### UPF-hypertension incidence claim (`ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md`) — cleanest claim in the batch The REGARDS + ELSA-Brasil dual replication, the specific biomarker mechanism (CRP, IL-6 → endothelial dysfunction), and the 14.5% per 100g meta-analysis figure are all well-cited and appropriately calibrated at `likely`. No issues. ### Cross-domain connection worth surfacing The UPF → chronic inflammation → antihypertensive failure chain directly connects to Rio's domain through the insurance economics angle: if 76.6% of treated hypertensives are uncontrolled despite medication access, and if dietary environment is a mechanistic contributor, then value-based care models that bear full cardiovascular risk have an economic case for SDOH/food environment intervention that the current fee-for-service structure cannot generate. This connection isn't made in the claims; it would strengthen the wiki-link graph. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Three issues need fixing: (1) `regulatory-deregulation-occurring-during-active-harm-accumulation` is a near-duplicate of an existing claim and should be merged or dropped; (2) `regulatory-rollback-clinical-ai-eu-us-2025-2026` uses "regulatory capture" in the title with more certainty than the evidence supports; (3) `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration` overclaims that UPF explains the 76.6% treatment failure rate (contradicting adherence literature) and is missing citations for the 76.6% figure and GLP-1 cardiovascular benefit statistic. The CVD/healthspan cluster, the healthspan-lifespan gap claims, and the multi-agent clinical AI claims are high quality and should merge once the three issues are resolved. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 07:32:20 +00:00
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 07:43:40 +00:00
m3taversal commented 2026-04-07 07:43:40 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2487
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?